ValiRx plc
VAL.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.08 | -0.15 | 0.40 |
| FCF Yield | -158.92% | -34.68% | -15.82% | -5.35% |
| EV / EBITDA | 0.28 | -2.86 | -4.10 | -15.89 |
| Quality | ||||
| ROIC | -51.26% | -72.58% | -62.14% | -44.47% |
| Gross Margin | -436.41% | -2,562.95% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.77 | 0.66 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 21.92% | -21.39% | -35.83% | 37.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.83 | 0.07 | 0.46 | 0.37 |
| Interest Coverage | -1,674.49 | -520.15 | -475.33 | -606.81 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 3.70 | 0.00 | 0.00 |
| Cash Conversion Cycle | 748.77 | 3,686.53 | -40.61 | -20.83 |